(Pensacola, Fla. – March 19, 2015) – Pegasus Laboratories, makers of PRN® Pharmacal branded products, has named Ralph Claxton, MS, DVM as Pegasus Laboratories Director of Regulatory Affairs. Dr. Claxton will report to Donna Logan, Vice President of Compliance & Technical Services.
Ralph Claxton, MS, DVM
Dr. Claxton will provide regulatory strategy for both pre-market (developmental) and post-market veterinary products to ensure product compliance with FDA/CVM, EMEA and VDD regulations. The expansion of the company’s regulatory department is a direct result of the company’s rapidly expanding product portfolio. Dr. Claxton will be a key contributor to PRN Pharmacal’s New Products Development Team.
“We are pleased to have Dr. Claxton join the company. His credentials speak for themselves and his extensive experience in veterinary pharmaceutical R&D and regulatory affairs across multiple product categories will greatly contribute to the continued growth of PRN Pharmacal,” said Donna Logan, Vice President of Compliance & Technical Services.
Prior to joining PRN Pharmacal, Dr. Claxton was Director of Regulatory Affairs for Schafer Veterinary Consultants, LLC, Fort Collins, Colorado where he was responsible for providing project management and consulting services pursuant to FDA market authorization and regulatory submissions for all phases of product development.
Dr. Claxton has 23 years regulatory experience across a wide range of therapeutic categories and species at four other leading pharmaceutical companies. His most recent corporate position was as Associate Director/Senior Manager at Boehringer-Ingelheim Vetmedica. He also served as Senior Manager Pharmaceutical Development and GCP Operations at Novartis Animal Health US. Before joining Novartis, Claxton served as Associate Director of Regulatory Affairs in the Biological Division at Merial. He began his animal health career with Fort Dodge Laboratories.
Dr. Claxton is an invited lecturer at professional veterinary meetings, classrooms and webinars, focusing on FDA drug development, GXP compliance, and pharmacology including pharmacokinetics and bioanalytical method validation. He is a Fellow and Executive Council member of the American Academy of Veterinary Pharmacology and Therapeutics, serving as Treasurer for that organization. He has also held the position of Chair, Animal Health Institute Working Group on Pharmacokinetics in Drug Development. He is also a member of the American Veterinary Medical Association. Dr. Claxton has published research articles extensively in peer-reviewed journals including the Journal of Veterinary Pharmacology and Therapeutics.
Dr. Claxton graduated from Mercer University with a Bachelor of Science degree. He earned his Master of Science degree from the University of Georgia College of Pharmacy and earned a Doctorate in Veterinary Medicine from the University of Georgia. He is a member of the Phi Theta Veterinary Honor Society, the Sigma XI National Research Honor Society and the Alpha Psi Professional Veterinary Fraternity.
“I am honored to be a part of the team moving PRN Pharmacal to the next level of portfolio expansion in this dynamic and exciting time in the veterinary pharmaceutical industry. PRN Pharmacal’s commitment to quality and compliance in serving customers at all levels is the core strength of this company. I look forward to helping advance this effort in new drug approvals as we move ahead,” said Dr. Claxton.
Pegasus Laboratories manufactures products, which are distributed and marketed to the veterinary profession under the name PRN Pharmacal. Brand names include PROIN® for canine urinary incontinence and Collasate Silver® gel. To learn more about PRN Pharmacal products, visit www.PRNPharmacal.com or call 1-800-874-9764.
###
